Jci_page_head_homepage_01 Jci_page_head_homepage_02
Lisa A. Palmer, Allan Doctor, Preeti Chhabra, Mary Lynn Sheram, Victor E. Laubach, Molly Z. Karlinsey, Michael S. Forbes, Timothy Macdonald, Benjamin Gaston
Published in Volume 117, Issue 9
J Clin Invest. 2007; 117(9):2592–2601 doi:10.1172/JCI29444
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
SNOAC recapitulates in primary pulmonary arterial endothelial cells the hypoxia-mimetic whole-lung effect of chronic NAC administration on Sp3 expression in vivo.

(A) One micromolar SNOAC, but not 50 μM NAC, treatment (4 hours each) increased intracellular S-nitrosothiol levels (assayed by Cu/cysteine chemiluminescence; ref. 11) in primary murine pulmonary endothelial cells (*P < 0.05 compared with SNOAC treatment). (B) Immunoblot showing increased Sp3 expression relative to MAPK in the whole-lung homogenates of mice treated for 3 weeks with 10 mg/ml NAC but not in those of control mice. By densitometry, this increase was significant (P < 0.01). (C) Paradoxically, however, NAC (50 μM; 4 hours) did not increase Sp3 expression relative to β-actin in primary murine pulmonary endothelial cells in vitro, while both SNOAC (1 μM; 4 hours) and hypoxia (10%; 4 hours) did.